Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial
在接受一线化疗的小细胞肺癌患者中,使用 CDK4/6 抑制剂 trilaciclib 进行骨髓保护:一项 Ib 期/随机 II 期试验
期刊:Annals of Oncology
影响因子:65.4
doi:10.1093/annonc/mdz278
Weiss, J M; Csoszi, T; Maglakelidze, M; Hoyer, R J; Beck, J T; Domine Gomez, M; Lowczak, A; Aljumaily, R; Rocha Lima, C M; Boccia, R V; Hanna, W; Nikolinakos, P; Chiu, V K; Owonikoko, T K; Schuster, S R; Hussein, M A; Richards, D A; Sawrycki, P; Bulat, I; Hamm, J T; Hart, L L; Adler, S; Antal, J M; Lai, A Y; Sorrentino, J A; Yang, Z; Malik, R K; Morris, S R; Roberts, P J; Dragnev, K H